Nab-paclitaxel-oxaliplatin-S-1 vs FOLFOX in locally advanced gastric cancer: Efficacy and postoperative disease-free survival prediction

Table 1 Basic patient characteristics and short-term efficacy, n (%)

Characteristic	Overall (n = 181)	FOLFOX (n = 68)	P-SOX (n = 113)	Statistic	P value1
Age				χ2 = 0.02	0.894
0	100 (55.2)	38 (55.9)	62 (54.9)
1	81 (44.8)	30 (44.1)	51 (45.1)
Sex				χ2 = 0.09	0.763
1	151 (83.4)	56 (82.4)	95 (84.1)
2	30 (16.6)	12 (17.6)	18 (15.9)
cT				χ2 = 0.28	0.868
2	40 (22.1)	16 (23.5)	24 (21.2)
3	92 (50.8)	35 (51.5)	57 (50.4)
4	49 (27.1)	17 (25.0)	32 (28.3)
cN				χ2 = 0.05	0.825
0	55 (30.4)	20 (29.4)	35 (31.0)
1	126 (69.6)	48 (70.6)	78 (69.0)
cTNM				χ2 = 2.00	0.572
1	87 (48.1)	37 (54.4)	50 (44.2)
2	21 (11.6)	6 (8.8)	15 (13.3)
3	33 (18.2)	11 (16.2)	22 (19.5)
4	40 (22.1)	14 (20.6)	26 (23.0)
ASA				χ2 = 0.39	0.530
0	153 (84.5)	56 (82.4)	97 (85.8)
1	28 (15.5)	12 (17.6)	16 (14.2)
Differentiation				χ2 = 0.28	0.871
1	50 (27.6)	18 (26.5)	32 (28.3)
2	53 (29.3)	19 (27.9)	34 (30.1)
3	78 (43.1)	31 (45.6)	47 (41.6)
RECIST 11				χ2 = 1.60	0.206
0	77 (42.5)	33 (48.5)	44 (38.9)
1	104 (57.5)	35 (51.5)	69 (61.1)
TRG				χ2 = 1.16	0.281
0	51 (28.2)	16 (23.5)	35 (31.0)
1	130 (71.8)	52 (76.5)	78 (69.0)
Tumor diameter				χ2 = 4.57	0.102
1	73 (40.3)	34 (50.0)	39 (34.5)
2	68 (37.6)	20 (29.4)	48 (42.5)
3	40 (22.1)	14 (20.6)	26 (23.0)
Location				χ2 = 0.35	0.839
1	41 (22.7)	14 (20.6)	27 (23.9)
2	73 (40.3)	29 (42.6)	44 (38.9)
3	67 (37.0)	25 (36.8)	42 (37.2)

¹Pearson’s χ² test.

Tumor location is classified as upper 1/3, middle 1/3, lower 1/3, diffuse tumor node metastasis staging. cTNM: Clinical tumor node metastasis; ASA: American Society of Anesthesiologists Score; RECIST: Response evaluation criteria in solid tumors; TRG: Tumor regression grade.

Table 2 Side effects associated with two groups treatment, n (%)

Variables	Total (n = 181)	FOLFOX (n = 68)	P-SOX (n = 113)	Statistic	P value
Nausea and vomiting					0.123
0	42 (23.20)	13 (19.12)	29 (25.66)
1	101 (55.80)	35 (51.47)	66 (58.41)
2	34 (18.78)	17 (25.00)	17 (15.04)
3	4 (2.21)	3 (4.41)	1 (0.88)
Liver toxicity				-	0.165
0	151 (83.43)	58 (85.29)	93 (82.30)
1	26 (14.36)	7 (10.29)	19 (16.81)
2	4 (2.21)	3 (4.41)	1 (0.88)
Alopecia				χ2 = 3.03	0.220
0	94 (51.93)	36 (52.94)	58 (51.33)
1	74 (40.88)	30 (44.12)	44 (38.94)
2	13 (7.18)	2 (2.94)	11 (9.73)
Peripheral sensory neuropathy					0.790
0	91 (50.28)	35 (51.47)	56 (49.56)
1	72 (39.78)	26 (38.24)	46 (40.71)
2	16 (8.84)	7 (10.29)	9 (7.96)
3	2 (1.10)	0 (0.00)	2 (1.77)
Fewer neutrophils					0.387
0	132 (72.93)	45 (66.18)	87 (76.99)
1	34 (18.78)	16 (23.53)	18 (15.93)
2	7 (3.87)	4 (5.88)	3 (2.65)
3	7 (3.87)	3 (4.41)	4 (3.54)
4	1 (0.55)	0 (0.00)	1 (0.88)
Fewer white blood cells					0.027
0	102 (56.35)	43 (63.24)	59 (52.21)
1	54 (29.83)	14 (20.59)	40 (35.40)
2	16 (8.84)	8 (11.76)	8 (7.08)
3	5 (2.76)	0 (0.00)	5 (4.42)
4	4 (2.21)	3 (4.41)	1 (0.88)
Fewer platelets					0.521
0	133 (73.48)	52 (76.47)	81 (71.68)
1	31 (17.13)	10 (14.71)	21 (18.58)
2	12 (6.63)	3 (4.41)	9 (7.96)
3	5 (2.76)	3 (4.41)	2 (1.77)
Anemia				χ2 = 2.64	0.450
0	94 (51.93)	36 (52.94)	58 (51.33)
1	62 (34.25)	21 (30.88)	41 (36.28)
2	15 (8.29)	5 (7.35)	10 (8.85)
3	10 (5.52)	6 (8.82)	4 (3.54)

Table 3 Results of multivariate Cox proportional hazards regression analyses

Characteristic	n	Event n	HR	95%CI	P value
cT
2	29	19
3	67	44	0.88	0.45-1.70	0.694
4	31	25	1.17	0.49-2.79	0.721
cN
0	40	24
1	87	64	1.46	0.86-2.49	0.166
cTNM
1	57	26
2	16	11	1.78	0.83-3.81	0.141
3	28	27	3.30	1.70-6.39	< 0.001
4	26	24	5.42	2.34-12.54	< 0.001
Differentiation
1	36	19
2	37	21	0.94	0.49-1.81	0.863
3	54	48	1.31	0.73-2.33	0.363
RECIST 11
0	53	43
1	74	45	0.67	0.42-1.08	0.098
TRG
0	35	31
1	92	57	0.51	0.31-0.83	0.007
Tumor diameter
1	51	30
2	50	35	1.38	0.82-2.35	0.228
3	26	23	2.93	1.55-5.55	< 0.001

CI: Confidence interval; HR: Hazard ratio; cTNM: Clinical tumor node metastasis; RECIST: Response evaluation criteria in solid tumors; TRG: Tumor regression grade.